A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial

EuroIntervention 2018;14:86-93 published online March 2018. DOI: 10.4244/EIJ-D-17-00890

Valeria Paradies
Valeria Paradies1, MD; Ori Ben-Yehuda2, MD; Michael Jonas3, MD; Shmuel Banai4, MD; Andres Iñiguez5, MD; Gidon Y. Perlman6, MD; David E. Kandzari7, MD; Gregg W. Stone2, MD; Pieter C. Smits1*, MD, PhD
1. Maasstad Hospital, Rotterdam, the Netherlands; 2. Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA; 3. Kaplan Medical Center, Rechovot, Israel; 4. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 5. Ho

Aims: The aim of this study was to evaluate the efficacy and safety of the BioNIR stent compared with the Resolute Integrity stent for the treatment of coronary artery disease.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

coronary artery diseaseclinical researchqca
Stents and scaffolds
Read next article
Overview and proposed terminology for the reverse controlled antegrade and retrograde tracking (reverse CART) techniques

Latest news